Dexamethasone suppresses beta-endorphin in humans.

Area of Science:

• Endocrinology
• Neuroscience

Background:

• Glucocorticoid effects on beta-endorphin regulation in humans are inconsistently reported.
• Previous studies may be affected by assay methodology limitations.

Purpose of the Study:

• To clarify the effect of dexamethasone on plasma beta-endorphin levels using a specific assay.
• To investigate the impact of assay specificity on detecting dexamethasone-induced changes.

Main Methods:

• Six healthy subjects received oral dexamethasone (2 mg) or placebo.
• Plasma immunoreactive beta-endorphin (irB-EP) was measured using a highly specific assay.
• A less specific assay was used for comparison.

Main Results:

• Dexamethasone significantly suppressed plasma irB-EP levels (15.3 to 9.1 pg/ml, p<0.01).
• Cortisol levels were also suppressed by dexamethasone.
• The less specific assay did not detect significant changes in irB-EP after dexamethasone administration.

Conclusions:

• A specific assay confirms that dexamethasone suppresses plasma beta-endorphin in humans.
• Assay methodology is critical for accurately assessing dexamethasone's effect on beta-endorphin.
• Methodological artifacts in less specific assays likely explain prior conflicting results.